$0.00 EPS Expected for Mountain Province Diamonds, Inc. (MPVD), Oncomed Pharmaceuticals (OMED) Sellers Decreased By 13.28% Their Shorts

Analysts expect Mountain Province Diamonds, Inc. (NASDAQ:MPVD) to report $0.00 EPS on May, 11. The stock increased 3.77% or $0.1 on May 9, reaching $2.75. About shares traded. Mountain Province Diamonds, Inc. (NASDAQ:MPVD) has declined 45.06% since October 3, 2016 and is downtrending. It has underperformed by 55.97% the S&P500.

Oncomed Pharmaceuticals Incorporated (NASDAQ:OMED) had a decrease of 13.28% in short interest. OMED’s SI was 2.46M shares in May as released by FINRA. Its down 13.28% from 2.83 million shares previously. With 153,100 avg volume, 16 days are for Oncomed Pharmaceuticals Incorporated (NASDAQ:OMED)’s short sellers to cover OMED’s short positions. The SI to Oncomed Pharmaceuticals Incorporated’s float is 11.06%. The stock increased 2.17% or $0.08 during the last trading session, reaching $3.77. About shares traded. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has declined 67.67% since October 3, 2016 and is downtrending. It has underperformed by 78.57% the S&P500.

OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $144.98 million. The Firm focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. It currently has negative earnings. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).

Investors sentiment decreased to 1.12 in 2016 Q4. Its down 1.07, from 2.19 in 2016Q3. It turned negative, as 10 investors sold Oncomed Pharmaceuticals Inc shares while 23 reduced holdings. 9 funds opened positions while 28 raised stakes. 13.60 million shares or 0.82% less from 13.71 million shares in 2016Q3 were reported. Citigroup Inc holds 0% of its portfolio in Oncomed Pharmaceuticals Inc (NASDAQ:OMED) for 600 shares. State Common Retirement Fund accumulated 17,600 shares. Highbridge Management Limited Liability Company invested in 36,674 shares. Blackrock Management Ltd owns 0% invested in Oncomed Pharmaceuticals Inc (NASDAQ:OMED) for 86,206 shares. Schwab Charles Management invested 0% of its portfolio in Oncomed Pharmaceuticals Inc (NASDAQ:OMED). Renaissance Lc owns 469,300 shares or 0.01% of their US portfolio. Sei Company invested in 0% or 132 shares. State Street reported 0% in Oncomed Pharmaceuticals Inc (NASDAQ:OMED). Walleye Trading Ltd Liability Corp reported 0% stake. Prelude Cap Mngmt Ltd Llc holds 0% or 656 shares. Tiaa Cref Mngmt Lc holds 58,329 shares. Citadel Advisors Lc holds 18,306 shares or 0% of its portfolio. Cannell Peter B has 0.07% invested in Oncomed Pharmaceuticals Inc (NASDAQ:OMED) for 252,228 shares. 899,991 were reported by Vanguard Gp. Moreover, Franklin Inc has 0% invested in Oncomed Pharmaceuticals Inc (NASDAQ:OMED).

Since November 16, 2016, it had 0 buys, and 11 sales for $1.02 million activity. $52,113 worth of stock was sold by Hoey Timothy on Tuesday, April 4. Another trade for 4,316 shares valued at $39,089 was made by Hager Alicia J. on Tuesday, April 4. Lewicki John A. had sold 5,754 shares worth $52,113 on Tuesday, April 4. HASTINGS PAUL J sold $58,625 worth of stock. 5,754 Oncomed Pharmaceuticals Inc (NASDAQ:OMED) shares with value of $52,113 were sold by Patel Sunil. Another trade for 5,754 shares valued at $52,113 was sold by Gurney Austin.

Among 9 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. OncoMed Pharmaceuticals had 13 analyst reports since September 9, 2015 according to SRatingsIntel. The rating was downgraded by Leerink Swann to “Mkt Perform” on Monday, January 25. The firm has “Buy” rating by Mizuho given on Tuesday, January 26. Mizuho maintained it with “Neutral” rating and $40 target in Wednesday, January 6 report. Cantor Fitzgerald initiated it with “Buy” rating and $16 target in Monday, April 18 report. The stock has “Market Perform” rating by BMO Capital Markets on Tuesday, April 11. The company was initiated on Tuesday, December 20 by SunTrust. The firm has “Buy” rating given on Wednesday, August 10 by Jefferies. The stock of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. The stock of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The firm has “Buy” rating given on Thursday, September 22 by H.C. Wainwright.